We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

357 hedge funds and large institutions have $8.94B invested in Jazz Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 126 increasing their positions, 120 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 36

25% more funds holding in top 10

Funds holding in top 10: 1215 (+3)

10% more funds holding

Funds holding: 325357 (+32)

5% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 120

4% more capital invested

Capital invested by funds: $8.58B → $8.94B (+$355M)

27% less call options, than puts

Call options by funds: $86.4M | Put options by funds: $119M

Holders
357
Holders Change
+32
Holders Change %
+9.85%
% of All Funds
9.52%
Holding in Top 10
15
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+25%
% of All Funds
0.4%
New
76
Increased
126
Reduced
120
Closed
36
Calls
$86.4M
Puts
$119M
Net Calls
-$32.4M
Net Calls Change
+$92.4M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
201
Atika Capital Management
New York
$1.16M -$1.15M -6,900 -49%
GL
202
GLG LLC
New York
$1.15M -$1.36M -8,200 -54%
HHC
203
Hutchin Hill Capital
New York
$1.06M -$614K -3,700 -36%
AB
204
Amalgamated Bank
New York
$1.06M +$5.81K +35 +0.5%
CA
205
Commerzbank Aktiengesellschaft
Germany
$1.03M +$670K +4,036 +178%
CSS
206
Cubist Systematic Strategies
Connecticut
$1.03M +$754K +4,541 +257%
PG
207
PEAK6 Group
Illinois
$1.02M +$382K +2,304 +59%
OSAM
208
O'Shaughnessy Asset Management
Connecticut
$960K -$1.63M -9,815 -63%
GF
209
Gerstein Fisher
New York
$960K
HCM
210
Herndon Capital Management
Georgia
$948K +$962K +5,793 New
BCIM
211
British Columbia Investment Management
British Columbia, Canada
$944K +$957K +5,766 New
PA
212
Profund Advisors
Maryland
$942K +$99.6K +600 +12%
CFA
213
Camarda Financial Advisors
Florida
$925K +$277K +1,668 +42%
USGIU
214
U.S. Global Investors (USGI)
Texas
$901K +$83K +500 +10%
CCIA
215
Campbell & Co Investment Adviser
Maryland
$901K +$913K +5,500 New
Connor, Clark & Lunn Investment Management (CC&L)
216
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$868K -$3.3M -19,900 -79%
NA
217
Navellier & Associates
Nevada
$863K -$13.3K -80 -1%
AHC
218
Adell Harriman & Carpenter
Texas
$827K +$838K +5,050 New
PVI
219
Pura Vida Investments
New York
$819K +$830K +5,000 New
Commonwealth Equity Services
220
Commonwealth Equity Services
Massachusetts
$802K +$114K +686 +16%
SMDAM
221
Sumitomo Mitsui DS Asset Management
Japan
$790K +$801K +4,827 New
NI
222
Numeric Investors
Massachusetts
$786K +$797K +4,800 New
HR
223
Howe & Rusling
New York
$781K -$10.6K -64 -1%
CIG
224
Consolidated Investment Group
Colorado
$756K +$46K +277 +6%
Fifth Third Bancorp
225
Fifth Third Bancorp
Ohio
$750K -$12.1K -73 -2%

JAZZ Hedge Fund Activity: Q4 2014 in Review

357 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2014, worth a combined $8.94B — up 4.1% from $8.58B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 36 closed out — a net gain of 40 holders — while 126 added to existing stakes and 120 trimmed.

The largest buyer was American Century Companies, adding an estimated $71.4M. The largest seller was Wells Fargo, cutting an estimated $119M.

  • 357 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2014, up from 325 in Q3 2014.
  • Funds reported $8.94B of Jazz Pharmaceuticals stock for Q4 2014, up 4.1% quarter-over-quarter.
  • 76 funds opened new Jazz Pharmaceuticals positions in Q4 2014 and 36 closed out, a net change of +40 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2014 was American Century Companies, an estimated $71.4M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2014 was Wells Fargo, an estimated $119M sold.

Based on aggregated 13F filings for Q4 2014.